Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eco Animal Health GroupLSE:EAH +10.38%55 Return-on-Tangible-Equity is 12.10% as of Mar. 2026, which is 65% above its 10-year median of 7.33. GuruFocus rates LSE:EAH with a GF Score™ of 55/100 and a GF Value™ of £1.00 (Fairly Valued). The stock has 3 warning signs investors should review. Among 899 Drug Manufacturers companies, Eco Animal Health Group ranks worse than 58.4% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Eco Animal Health Group's annualized net income for the quarter that ended in Mar. 2026 was £5.11 Mil. Eco Animal Health Group's average shareholder tangible equity for the quarter that ended in Mar. 2026 was £42.20 Mil. Therefore, Eco Animal Health Group's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 12.10%.
The historical rank and industry rank for Eco Animal Health Group's Return-on-Tangible-Equity or its related term are showing as below:
LSE:EAH'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -1.47 Med: 7.33 Max: 29.04
Current: 5.13
During the past 13 years, Eco Animal Health Group's highest Return-on-Tangible-Equity was 29.04%. The lowest was -1.47%. And the median was 7.33%.
LSE:EAH's Return-on-Tangible-Equity is ranked worse than 58.4% of 899
companies
in the Drug Manufacturers industry
Industry Median: 7.95
vs LSE:EAH: 5.13
Eco Animal Health Group (LSE:EAH) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Eco Animal Health Group Return-on-Tangible-Equity Related Terms
Eco Animal Health Group Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Eco Animal Health Group's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eco Animal Health Group Return-on-Tangible-Equity Chart
LSE:EAH vs ZTS, UTHR, VTRS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Eco Animal Health Group's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eco Animal Health Group Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eco Animal Health Group's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Eco Animal Health Group's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 12.10% mean?
Eco Animal Health Group (LSE:EAH) has a Return-on-Tangible-Equity of 12.10% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Eco Animal Health Group and its competitors. This is 65% above median its historical median of 7.33. According to the industry distribution chart, Eco Animal Health Group ranks #525 out of 899 companies in the Drug Manufacturers industry, placing it in the top 58.4%.
Is Eco Animal Health Group's Return-on-Tangible-Equity too high?
Eco Animal Health Group's current Return-on-Tangible-Equity of 12.10% is 65% above median its 10-year median of 7.33. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.95. Eco Animal Health Group's value of 12.10% is 52.2% above this industry median. Based on the distribution chart, Eco Animal Health Group ranks #525 out of 899 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Eco Animal Health Group has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Eco Animal Health Group's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Eco Animal Health Group ranks #525 out of 899 companies for Return-on-Tangible-Equity. This places Eco Animal Health Group in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.95. Eco Animal Health Group's value of 12.10% is 52.2% above this benchmark. While the company's 10-year median is 7.33 vs. the industry median of 7.95, Eco Animal Health Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.95, based on 899 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eco Animal Health Group's current Return-on-Tangible-Equity of 12.10% is 52.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Eco Animal Health Group and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eco Animal Health Group's current Return-on-Tangible-Equity is 12.10%, which is 65% above median its own 10-year median of 7.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eco Animal Health Group stock overvalued right now?
Based on GuruFocus' analysis, Eco Animal Health Group (LSE:EAH) is currently considered Fairly Valued. The stock's GF Value™ is £1.00, compared to a current price of £1.01 — trading 1% above its estimated fair value. The current Return-on-Tangible-Equity is 12.10%, which is 65% above median its 10-year median of 7.33 and 52.2% above the Drug Manufacturers industry median of 7.95. Eco Animal Health Group's overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Eco Animal Health Group (LSE:EAH), the current Return-on-Tangible-Equity is 12.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eco Animal Health Group (LSE:EAH) Overvalued in 2026?
Based on GuruFocus' analysis, Eco Animal Health Group stock appears to be overvalued.
The current stock price of £1.01 is trading 1% above its estimated GF Value™ of £1.00.
GuruFocus considers Eco Animal Health Group to be Fairly Valued.
Key valuation signals for LSE:EAH:
Return-on-Tangible-Equity: 12.10% (65% above median its 10-year median of 7.33)
GF Value™: £1.00 vs. price of £1.01 (1% above fair value)
Industry Position: 52.2% above the Drug Manufacturers median (#525 of 899)
No single metric tells the full story. See the LSE:EAH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eco Animal Health Group PLC is an animal health biotech company. It provides quality products for swine and poultry, anti-infectives to treat illness, improve health, and performance. Its products include Aivlosin/Valosin Solutions and Parasite Solutions. The company's segments include Corporate/UK, China and Japan, North America, South and Southeast Asia, Latin America, Europe, and the Rest of the World, with the majority of the revenue deriving from China and Japan.
55GF Score
Get the complete analysis for LSE:EAH
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:EAH has been successfully added to your 
